公开(公告)号：EP2805746B1

公开(公告)日：2020-05-06

申请号：EP14170446.0

申请日：2010-02-16

申请人： Nogra Pharma Limited

发明人： Baroni, Sergio ,  Bellinvia, Salvatore ,  Viti, Francesca

IPC分类号： A61K31/196 ,  A61K31/42 ,  A61Q19/02 ,  A61Q19/06 ,  A61Q19/08 ,  C07D319/08 ,  C07C233/54 ,  C07D307/79 ,  A61K8/42

公开(公告)号：EP3744398A1

公开(公告)日：2020-12-02

申请号：EP20172608.0

申请日：2010-02-16

申请人： Nogra Pharma Limited

发明人： Baroni, Sergio ,  Bellinvia, Salvatore ,  Viti, Francesca

IPC分类号： A61P17/00 ,  A61K31/167 ,  A61P3/00 ,  A61P35/00 ,  A61P29/00 ,  A61K8/42 ,  A61Q19/02 ,  A61Q19/06 ,  A61Q19/08 ,  C07D319/08 ,  C07C233/54 ,  C07D307/79

摘要： Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.

公开(公告)号：EP3165929A3

公开(公告)日：2017-06-21

申请号：EP16184629.0

申请日：2012-09-14

申请人： Nogra Pharma Limited

发明人： Monteleone, Giovanni ,  Viti, Francesca ,  Bellinvia, Salvatore

IPC分类号： G01N33/68 ,  G01N33/50

CPC分类号： G01N33/56972 ,  G01N33/505 ,  G01N33/5094 ,  G01N33/6866 ,  G01N33/6869 ,  G01N33/6872 ,  G01N2333/54 ,  G01N2333/7158 ,  G01N2800/065 ,  G01N2800/52

摘要： Methods for monitoring whether a subject will be sensitive or resistant to treatment with an anti-SMAD7 therapy are disclosed. The methods are based on the determining of the amount of CCR9+ FOXP3+ T cells, CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FOXP3+ T cells, IFN-gamma+ T cells, and/or IL17A+ T cells in a sample from the subject. Measurement of T cell populations may be determined by flow cytometry, immunohistochemsistry, and/or ELISA.

摘要翻译： 公开了用于监测受试者是否对用抗SMAD7疗法治疗敏感或耐受的方法。 该方法基于确定来自受试者的样品中CCR9 + FOXP3 + T细胞，CCR9 + IFN-γ+ T细胞，CCR9 + IL17A + T细胞，FOXP3 + T细胞，IFN-γ+ T细胞和/或IL17A + T细胞的量 。 T细胞群的测量可以通过流式细胞术，免疫组织化学和/或ELISA来测定。

公开(公告)号：EP3165929A2

公开(公告)日：2017-05-10

申请号：EP16184629.0

申请日：2012-09-14

申请人： Nogra Pharma Limited

发明人： Monteleone, Giovanni ,  Viti, Francesca ,  Bellinvia, Salvatore

IPC分类号： G01N33/68 ,  G01N33/50

CPC分类号： G01N33/56972 ,  G01N33/505 ,  G01N33/5094 ,  G01N33/6866 ,  G01N33/6869 ,  G01N33/6872 ,  G01N2333/54 ,  G01N2333/7158 ,  G01N2800/065 ,  G01N2800/52

摘要： Methods for monitoring whether a subject will be sensitive or resistant to treatment with an anti-SMAD7 therapy are disclosed. The methods are based on the determining of the amount of CCR9+ FOXP3+ T cells, CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FOXP3+ T cells, IFN-gamma+ T cells, and/or IL17A+ T cells in a sample from the subject. Measurement of T cell populations may be determined by flow cytometry, immunohistochemsistry, and/or ELISA.

公开(公告)号：EP2805746A1

公开(公告)日：2014-11-26

申请号：EP14170446.0

申请日：2010-02-16

申请人： Nogra Pharma Limited

发明人： Baroni, Sergio ,  Bellinvia, Salvatore ,  Viti, Francesca

IPC分类号： A61P17/00 ,  A61K31/167 ,  A61P3/00 ,  A61P35/00 ,  A61P29/00 ,  A61K8/42 ,  A61Q19/02 ,  A61Q19/06 ,  A61Q19/08 ,  C07D319/08 ,  C07C233/54 ,  C07D307/79

摘要： Disclosed herein are compounds of formula (I) that may be specific to PPAR and/or EGF receptors, and methods of making and using same.

wherein X is C 1 -C 3 alkylene, optionally substituted with one, two or three substituents selected from halogen or hydroxyl;
R 1 is selected from the group consisting of C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl;
R 2 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
R 3 is independently selected, for each occurrence from the group consisting of hydrogen, C 1 -C 6 alkoxy, C 1 -C 6 alkyl, cyano, C 3 -C 6 cycloalkyl, halogen, hydroxyl, and nitro;
R 4 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
R 5 is hydrogen C 1 -C 6 alkyl;
or pharmaceutically acceptable salts or N-oxides thereof.

摘要翻译： 本文公开了可以对PPAR和/或EGF受体特异的式（I）化合物及其制备和使用方法。 其中X是任选被1,2或3个选自卤素或羟基的取代基取代的C 1 -C 3亚烷基; R 1选自C 1 -C 6烷基，C 3 -C 6环烷基，C 2 -C 6烯基和C 2 -C 6炔基; R 2选自氢和C 1 -C 6烷基; R 3各自独立地选自氢，C 1 -C 6烷氧基，C 1 -C 6烷基，氰基，C 3 -C 6环烷基，卤素，羟基和硝基; R 4选自氢和C 1 -C 6烷基; R 5是氢C 1 -C 6烷基; 或其药学上可接受的盐或N-氧化物。